pipeline-prospector-insert-v1
X

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Armistice Capital

            Deal Size: $17.5 million Upfront Cash: Undisclosed

            Deal Type: Financing January 22, 2020

            Details:

            The company intends to use the net proceeds from the registered direct offering and concurrent private placement for the commercialization of XERAVA as well as for working capital and other general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Entera Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination Agreement January 21, 2020

            Details:

            RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.